CDK9 and breast carcinoma: To investigate the in vitro anti-cancer efficacy of the CDK9-specific inhibitor, DRB, MCF-7 and T-47D breast cancer cells were exposed to various concentrations of DRB for up to 72 h, and cell viability was determined by MTT assays.